Relieva

Relieva

Upcoming
IPT
Cannabinoid
$RLV

Relieva is redefining therapeutic innovation through the world’s first proprietary cannabis and hemp pre-roll blend engineered for targeted pain relief. Leveraging advanced cannabinoid and terpene research, Relieva integrates scientific precision, sustainable production, and blockchain-enabled IP tokenization to establish a new benchmark in functional medicine innovation and therapeutic transparency.

Relieva

Community Sentiment

How do you feel about this ipt?

...
No trend data
Project

Market Overview

$4.1 B
US pre-roll cannabis sales in 2024
606%
Infused pre-roll cannabis growth in 2024
$125 B
Global cannabis market by 2030

Summary

Relieva is a proprietary cannabis and hemp-derived pre-roll blend formulated for pain relief. Using New Leaf’s unique strain portfolio, it standardizes cannabinoid and terpene compositions to deliver consistent, therapeutic formulations for targeted wellness applications.

Problem

Current cannabis products lack standardized, scientifically validated formulations for pain relief. Consumers face inconsistent effects and limited access to compliant, data-driven solutions that bridge the gap between medical efficacy and wellness-oriented use.

Impact

Relieva pioneers functional, compliant cannabis formulations that combine plant science and technology to deliver consistent pain relief. By leveraging automated production and proprietary blends, it positions itself to lead the $125B global wellness cannabis market.

The project captures value by issuing tokens that grant holders fractional rights to revenue generated from intellectual property licensing. These tokens entitle users to a share of royalty streams, aligning incentives between IP creators and token holders.

Additionally, token ownership provides privileged access to data rooms, research and development updates, and opportunities for exclusive licensing. This model not only monetizes IP assets but also fosters a community of engaged stakeholders who benefit directly from the project’s commercial success.

Brendan de Kauwe

Brendan is a Financial Services Licence Responsible Manager with global capital markets experience, serving on NASDAQ and ASX boards. Since 2015, he’s led multiple tokenized RWA, DeFi, and blockchain ventures as founder and director.

Simon Owen

Simon is a corporate lawyer and advisor with 30 years’ experience in tech, biotech, fintech, and blockchain. He’s advised nearly 100 capital raisings and co-founded a pioneering blockchain investment firm, advising ventures across legal, regulatory, and strategic matters globally.

Andreas Gedeon

Andreas is a global cannabis industry leader with 10+ years’ experience as CEO and Director. He’s led firms through regulatory challenges, product development, and stock exchange listings across pharma and nutraceutical sectors in emerging and mature markets.

Steve James

Steve has 30+ years in financial services, holding senior roles at major banks and leading FX trading and broking ventures. Now CEO of ASX-listed DomaCom, he’s an experienced director with multiple qualifications in law, markets, governance, and corporate leadership.

Q1 2026

Phase I — Research & Formulation

Identify target outcomes and map active compound combinations

Phase II — Pilot Manufacturing

Produce small batches for lab and sensory testing under regulatory standards

Phase III — IP Protection

File patents and trademarks for novel formulations, processes, and branding

Phase IV — Brand & Regulatory Positioning

Establish compliant wellness product positioning with FDA and other regulators

Q1 2027

Phase V — Market Testing

Soft launch via pilot retail or e-commerce channels to gather consumer insights and early revenues

Community
Feed
...
Announcements

No announcements yet

Come back at a later point

Stay up to date

Get the latest community updates and find out about upcoming Relieva developments